Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Mendeley Supplemental Figures for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial. J Am Acad Dermatol. 2022.
创建时间：
2022-10-14
